Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha ( ) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patien...

Full description

Bibliographic Details

Published in:	Leukemia & lymphoma 2023-12, Vol.64 (12), p.1992-2001
Main Authors:	Stein, Eytan M, de Botton, Stephane, Cluzeau, Thomas, Pigneux, Arnaud, Liesveld, Jane L, Cook, Rachel J, Rousselot, Philippe, Rizzieri, David A, Braun, Thorsten, Roboz, Gail J, Lebon, Delphine, Heiblig, Mael, Baker, Kristen, Volkert, Angela, Paul, Sofia, Rajagopal, Nisha, Roth, David A, Kelly, Michael, Peterlin, Pierre
Format:	Article
Language:	English
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Azacitidine - therapeutic use Human health and pathology Humans Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Life Sciences Myelodysplastic Syndromes - genetics Retinoic Acid Receptor alpha
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!